Alpha 1-antitrypsin deficiency overview: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
|||
| Line 2: | Line 2: | ||
{{Alpha 1-antitrypsin deficiency}} | {{Alpha 1-antitrypsin deficiency}} | ||
{{CMG}}; {{AE}} {{CZ}} | {{CMG}}; {{AE}} {{CZ}} | ||
{{Pleasehelp}} | |||
==Overview== | ==Overview== | ||
| Line 21: | Line 23: | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
===Natural history=== | |||
===Complications=== | |||
===Prognosis=== | |||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Criteria=== | |||
===History and Symptoms=== | ===History and Symptoms=== | ||
| Line 29: | Line 38: | ||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
=== | ===Imaging Findings=== | ||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
Revision as of 13:03, 20 July 2016
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency overview On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency overview |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Alpha 1-antitrypsin deficiency (A1AD or Alpha-1) is a genetic disorder caused by defective production of alpha 1-antitrypsin, deficient activity in the blood and lungs, and deposition of excessive amounts of abnormal A1AT protein in liver cells.[1] There are several forms and degrees of deficiency. Severe A1A deficiency causes emphysema and/or COPD in adult life in nearly all people with the condition, various liver diseases in a minority of children and adults, and occasionally more unusual problems.[2] It is treated by avoidance of damaging inhalants, by intravenous infusions of the A1AT protein, by transplantation of liver or lungs, and by a variety of other measures, but it usually produces some degree of disability and shortens life.